NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma

Cancer Letters

Volumn 310, Issue 1, 2011, Pages 35-45

  Cheng, Jun ^a,b   Xie, Hai Yang ^a,b   Xu, Xiao ^a   Wu, Jian ^a   Wei, Xuyong ^b   Su, Rong ^b   Zhang, Wu ^b   Lv, Zhen ^b   Zheng Shusen, S ^a,b   Zhou, Lin ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; Metastasis; NDRG1; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; N MYC DOWNSTREAM REGULATED GENE 1 PROTEIN; REGULATOR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CELL ADHESION; CELL MEMBRANE TRANSPORT; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RNA INTERFERENCE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL CYCLE PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79961126505     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.001     Document Type: Article

References (38)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005, 55:74-108.
2. Llovet J.M., Fuster J., Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplantation 2004, 10:S115-120.
3. Jelic S. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2009, 20(4):41-45.
4. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, Md) 2005, 42:1208-1236.
5. Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616.
6. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., Herault A., Saric J., Belghiti J., Franco D., Bioulac-Sage P., Laurent-Puig P., Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (Baltimore, Md) 2007, 45:42-52.
7. Cheng J., Zhou L., Xie Q.F., Xie H.Y., Wei X.Y., Gao F., Xing C.Y., Xu X., Li L.J., Zheng S.S. The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics 2010, 10:1557-1572.
8. Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
9. Imamura H., Matsuyama Y., Tanaka E., Ohkubo T., Hasegawa K., Miyagawa S., Sugawara Y., Minagawa M., Takayama T., Kawasaki S., Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of Hepatology 2003, 38:200-207.
10. Iiizumi M., Liu W., Pai S.K., Furuta E., Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochimica et biophysica Acta 2008, 1786:87-104.
11. Ellen T.P., Ke Q., Zhang P., Costa M. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 2008, 29:2-8.
12. Sibold S., Roh V., Keogh A., Studer P., Tiffon C., Angst E., Vorburger S.A., Weimann R., Candinas D., Stroka D. Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for its membrane localization in human hepatocellular carcinoma. FEBS Letters 2007, 581:989-994.
13. Zheng S.S., Xu X., Wu J., Chen J., Wang W.L., Zhang M., Liang T.B., Wu L.M. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008, 85:1726-1732.
14. Chua M.S., Sun H., Cheung S.T., Mason V., Higgins J., Ross D.T., Fan S.T., So S. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Modern Pathology 2007, 20:76-83.
15. Zheng Y., Wang L.S., Xia L., Han Y.H., Liao S.H., Wang X.L., Cheng J.K., Chen G.Q. NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis. Proteomics 2009, 9:2064-2075.
16. Chen B., Nelson D.M., Sadovsky Y. N-myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury. The Journal of Biological Chemistry 2006, 281:2764-2772.
17. Salic A., Mitchison T.J. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:2415-2420.
18. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genetics 2004, 5:27.
19. Forner A., Reig M.E., de Lope C.R., Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Seminars in Liver Disease 2010, 30:61-74.
20. Marrero J.A., Fontana R.J., Barrat A., Askari F., Conjeevaram H.S., Su G.L., Lok A.S. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (Baltimore, Md) 2005, 41:707-716.
21. Mazzaferro V., Llovet J.M., Miceli R., Bhoori S., Schiavo M., Mariani L., Camerini T., Roayaie S., Schwartz M.E., Grazi G.L., Adam R., Neuhaus P., Salizzoni M., Bruix J., Forner A., De Carlis L., Cillo U., Burroughs A.K., Troisi R., Rossi M., Gerunda G.E., Lerut J., Belghiti J., Boin I., Gugenheim J., Rochling F., Van Hoek B., Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. The Lancet Oncology 2009, 10:35-43.
22. Qin L.X., Tang Z.Y. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. Journal of Cancer Research and Clinical Oncology 2004, 130:497-513.
23. Yi X., Luk J.M., Lee N.P., Peng J., Leng X., Guan X.Y., Lau G.K., Beretta L., Fan S.T. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Molecular and Cellular Proteomics 2008, 7:315-325.
24. Osada S., Saji S., Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. Journal of Surgical Oncology 2004, 85:48-54.
25. Akiba J., Ogasawara S., Kawahara A., Nishida N., Sanada S., Moriya F., Kuwano M., Nakashima O., Yano H. N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma. Oncology Reports 2008, 20:1329-1335.
26. Kitowska A., Pawelczyk T. N-myc downstream regulated 1 gene and its place in the cellular machinery. Acta Biochimica Polonica 2010, 57:15-21.
27. Zhou D., Salnikow K., Costa M. Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Research 1998, 58:2182-2189.
28. Toffoli S., Delaive E., Dieu M., Feron O., Raes M., Michiels C. NDRG1 and CRK-I/II are regulators of endothelial cell migration under Intermittent Hypoxia. Angiogenesis 2009, 12:339-354.
29. Zhang P., Tchou-Wong K.M., Costa M. Egr-1 mediates hypoxia-inducible transcription of the NDRG1 gene through an overlapping Egr-1/Sp1 binding site in the promoter. Cancer Research 2007, 67:9125-9133.
30. Maruyama Y., Ono M., Kawahara A., Yokoyama T., Basaki Y., Kage M., Aoyagi S., Kinoshita H., Kuwano M. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Research 2006, 66:6233-6242.
31. Guan R.J., Ford H.L., Fu Y., Li Y., Shaw L.M., Pardee A.B. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Research 2000, 60:749-755.
32. Song Y., Oda Y., Hori M., Kuroiwa K., Ono M., Hosoi F., Basaki Y., Tokunaga S., Kuwano M., Naito S., Tsuneyoshi M. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin. Human Pathology 2010, 41:214-222.
33. Strzelczyk B., Szulc A., Rzepko R., Kitowska A., Skokowski J., Szutowicz A., Pawelczyk T. Identification of high-risk stage II colorectal tumors by combined analysis of the NDRG1 gene expression and the depth of tumor invasion. Annals of Surgical Oncology 2009, 16:1287-1294.
34. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103:307-312.
35. Apte U., Zeng G., Muller P., Tan X., Micsenyi A., Cieply B., Dai C., Liu Y., Kaestner K.H., Monga S.P. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology (Baltimore, Md) 2006, 44:992-1002.
36. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., Mendell J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
37. Tu L.C., Yan X., Hood L., Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Molecular and Cellular Proteomics 2007, 6:575-588.
38. Banz V.M., Medova M., Keogh A., Furer C., Zimmer Y., Candinas D., Stroka D. Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta. Biochimica et biophysica Acta 2009, 1793:1597-1603.